Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Response Biomarkers
NCT07411651 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42
Last updated 2026-02-17
Summary
A wide variety of chemicals are constantly being introduced in our environment. The toxicological consequences related to the exposure to these compounds and their impact on public health ar of growing concern. It is now accepted that the occurrence of some non-communicable chronic diseases (diabetes, cancer, cardiovascular diseases…) is the result of complex interactions between environmental factors (chemical, physical and biological) and genetic factors. These non-communicable diseases have significantly increased in recent decades et have become the world's leading cause of deaths. Among these environmental factors, and in particular chemicals, the class of endocrine disruptors (EDs) is of particular concern. EDs are found ubiquitously in our environment. They are found in the natural environment (water, air, soil, etc.) as well as in everyday objects and our food. As a result, the general population is widely exposed to these EDs, which can be measured in a variety of biological media. The collection of biological matrices is essential for studying the exposure of populations to EDs. The choice of biological matrices depends on the physicochemical characteristics of the EDs studied and the type of exposure being assessed. Internal exposure to EDs is most often assessed through blood or urine concentrations in spot samples. Measuring urinary EDs concentrations remains a reference method for biomonitoring bisphenols and parabens. In order to assess long-term exposure to EDs, it was proposed to determine EDs concentrations in hair. In addition to these biological matrices for assessing general short-term and long-term exposure, the use of breast adipose tissue will enable in situ assessment of EDs exposure in the patients included. Moreover, adipose tissue represents an interesting biological matrix for determining exposure to pollutants with short half-lives, such as bisphenols and parabens, particularly when the latter have lipophilic characteristics. In addition, the use of this matrix will enable a non-targeted metabolomics approach to identify possible markers of biological response to EDs exposure, and to determine links between this exposure and carcinogenesis processes.
Conditions
- Breast Cancer
- Endocrine Disruptors
- Metabolomics
- Breast Lesions
Interventions
- OTHER
-
Collection of biological and clinical data
Collection of biological samples (hair, urine, breast adipose tissue) Collection of clinical and paraclinical data
Sponsors & Collaborators
-
Poitiers University Hospital
lead OTHER
Principal Investigators
-
Guillaume Binson, PharmD, PhD · Poitiers University Hospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-01
- Primary Completion
- 2027-02-01
- Completion
- 2027-02-01
Countries
- France
Study Locations
More Related Trials
-
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
NCT01874184 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer
NCT03731845 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
NCT03004534 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
NCT01553903 ·Status: COMPLETED ·Phase: PHASE4
-
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
NCT01612871 ·Status: COMPLETED ·Phase: PHASE4
-
Tamoxifen Citrate in Patients With Breast Cancer
NCT00963209 ·Status: UNKNOWN ·Phase: PHASE3
-
Hemostatic Profiles of Endocrine Therapies for Breast Cancer
NCT03381963 ·Status: COMPLETED
-
The Role of Diet and Lifestyle in Breast Cancer Survival
NCT00701584 ·Status: UNKNOWN
-
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
NCT00253539 ·Status: COMPLETED ·Phase: PHASE2
-
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
NCT06033092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
NCT02088710 ·Status: UNKNOWN
-
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
NCT04272801 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
NCT00316836 ·Status: COMPLETED
-
Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer
NCT04142476 ·Status: TERMINATED ·Phase: NA
-
Therapeutic Education Intervention in Breast Cancer: PEPs Hormonotherapy
NCT02300675 ·Status: COMPLETED ·Phase: NA
-
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
NCT06361940 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
NCT03351062 ·Status: RECRUITING ·Phase: PHASE3
-
Primary Hormone-sensitive Breast Cancer: Need-driven Health Care Improvement by Patient-centred Digital Application
NCT05503160 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Pharmacology of Adjuvant Hormonotherapy in Breast Cancer
NCT01127295 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Functional/Emotional Life Characteristics of Ongoing EAT in BC Patients With Reduced BMD
NCT05779566 ·Status: COMPLETED
-
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
NCT07106632 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Evaluation of Sexual Quality of Life for Breast Cancer
NCT04200001 ·Status: COMPLETED
-
Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+
NCT01220076 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment in Patients Affected by Breast Cancer
NCT03210441 ·Status: UNKNOWN
-
Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer
NCT01298362 ·Status: COMPLETED